Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) have received an average recommendation of “Moderate Buy” from the twenty research firms that are covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating […]
Hanseatic Management Services Inc. bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 4,559 shares of the company’s stock, valued at approximately $545,000. Neurocrine Biosciences comprises approximately 1.4% of Hanseatic Management Services Inc.’s investment portfolio, making the stock its 16th […]
Canaccord Genuity Group upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) from a hold rating to a buy rating in a research report report published on Thursday morning, MarketBeat.com reports. Canaccord Genuity Group currently has $132.00 price target on the stock, up from their previous price target of $124.00. NBIX has been the subject […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) – Stock analysts at Cantor Fitzgerald decreased their FY2023 EPS estimates for Neurocrine Biosciences in a research report issued to clients and investors on Tuesday, February 7th. Cantor Fitzgerald analyst C. Duncan now expects that the company will post earnings of $3.58 per share for the year, down […]
Operator: Good day, everyone, and welcome to today s Neurocrine Biosciences Reports Fourth Quarter and Year End Results. At this time, all participants are in a listen-only mode.